- Home
- BYSI vs ACOG Comparison
BYSI vs ACOG Comparison
Compare BYSI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- ACOG
- Stock Information
- Founded
- BYSI 2010
- ACOG 2000
- Country
- BYSI United States
- ACOG Canada
- Employees
- BYSI N/A
- ACOG N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- ACOG
- Sector
- BYSI Health Care
- ACOG
- Exchange
- BYSI Nasdaq
- ACOG Nasdaq
- Market Cap
- BYSI 71.0M
- ACOG 80.3M
- IPO Year
- BYSI 2017
- ACOG N/A
- Fundamental
- Price
- BYSI $2.18
- ACOG $10.18
- Analyst Decision
- BYSI
- ACOG Strong Buy
- Analyst Count
- BYSI 0
- ACOG 1
- Target Price
- BYSI N/A
- ACOG $20.00
- AVG Volume (30 Days)
- BYSI 92.5K
- ACOG 59.2K
- Earning Date
- BYSI 08-11-2025
- ACOG 08-14-2025
- Dividend Yield
- BYSI N/A
- ACOG N/A
- EPS Growth
- BYSI N/A
- ACOG N/A
- EPS
- BYSI N/A
- ACOG N/A
- Revenue
- BYSI N/A
- ACOG $2,928,654.00
- Revenue This Year
- BYSI N/A
- ACOG N/A
- Revenue Next Year
- BYSI N/A
- ACOG N/A
- P/E Ratio
- BYSI N/A
- ACOG N/A
- Revenue Growth
- BYSI N/A
- ACOG N/A
- 52 Week Low
- BYSI $0.98
- ACOG $3.75
- 52 Week High
- BYSI $3.44
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- BYSI 44.93
- ACOG N/A
- Support Level
- BYSI $2.15
- ACOG N/A
- Resistance Level
- BYSI $2.35
- ACOG N/A
- Average True Range (ATR)
- BYSI 0.13
- ACOG 0.00
- MACD
- BYSI -0.05
- ACOG 0.00
- Stochastic Oscillator
- BYSI 8.57
- ACOG 0.00
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.